Zhu MZL et al., 2024-12-25: Best-evidence review of seven studies (four RCTs, three observational) concluding that adjunctive methylene blue in post-bypass vasoplegia is safe and may improve haemodynamics and mortality.
The summation of the best available evidence, which was limited to small clinical trials and observational studies, suggests that the adjunctive administration of methylene blue for refractory post-CPB vasoplegic syndrome is safe and may provide benefits in terms of improved haemodynamic stability, reduction in vasopressor requirements and reduced mortality.
Zhu MZL et al., 2024-12-25: Best-evidence review of seven studies (four RCTs, three observational) concluding that adjunctive methylene blue in post-bypass vasoplegia is safe and may improve haemodynamics and mortality. C5. Study type: best evidence topic review (ICVTS structured protocol), 7 articles, single-centre studies with 30-120 patients each; Gold Coast University Hospital, Australia. Funder: Gold Coast Health Study, Education and Research Trust Account (per the record's grant field). Notes significant heterogeneity in timing and dosing of methylene blue and in the definition of vasoplegic syndrome, and that no study reported methylene-blue-related adverse events. Interdiscip Cardiovasc Thorac Surg 2024;40 (article number not in the abstract). Study type: review.
